Washington University School of Medicine
St Louis, Missouri, 63110, United States
NCT Number: NCT02148588
Prospective, open-label study in 10 patients with Central Post Stroke Pain (CPSP). The study will evaluate the effects of peripheral nerve blockade on spontaneous pain and evoked thermal and mechanical responses in CPSP, and assesses the associated local anesthetic pharmacokinetics.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
St Louis, Missouri, 63110, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Each subject must meet all of the following criteria:
Exclusion criteria
Subjects will not be enrolled if any of the following criteria exist:
Patients will have a peripheral nerve blockade with a local anesthetic (lidocaine)
Assessment of spontaneous and evoked pain responses
Completion of NPSI questionnaire
Mapping of the affected limb
Time frame: baseline and 30 minutes
Reduction in spontaneous pain intensity in the painful extremity from baseline to 30 minutes after a peripheral nerve block.Spontaneous pain intensity was measured on 0-10 numerical rating scale (NRS), where 0 represents "no pain", and 10 represents "worst pain imaginable"
Time frame: baseline and 30 min
The intensity of cold sensation (application of roller cooled down to 20 degrees Celsius) was measured on 0-10 scale, where 5 represents "normal" sensation (comparable to contralateral non-painful extremity). Higher scores indicate increased sensitivity (10= painful cold); lower scores represent reduced sensitivity (0=no cold sensation)
Time frame: baseline and 30 min
The intensity of warm sensation (application of roller heated up to 40 degrees Celsius) was measured on 0-10 scale, where 5 represents "normal" sensation (comparable to contralateral non-painful extremity). Higher scores indicate increased sensitivity (10= painful hot); lower scores represent reduced sensitivity (0=no warmth sensation)
Time frame: baseline and 30 min
The intensity of pinprick sensation (application of Semmes-Weinstein monofilament #6.1, ~100g target force) was measured on 0-10 scale, where 5 represents "normal" sensation (comparable to contralateral non-painful extremity). Higher scores indicate increased sensitivity (10= painful sharp); lower scores represent reduced sensitivity (0=no pricking sensation)
Time frame: baseline and 30 min
The intensity of brush sensation (application of SENSELab Brush-05) was measured on 0-10 scale, where 5 represents "normal" sensation (comparable to contralateral non-painful extremity). Higher scores indicate increased sensitivity (10= painful brushing sensation); lower scores represent reduced sensitivity (0=no brushing sensation)
Time frame: baseline and 40 min
Composite scores on NPSI (Neuropathic Pain Symptom Inventory) questionnaire before and 40 minutes after the peripheral nerve block.
The NPSI assesses participant ranking of specific neuropathic pain descriptors, each ranked on a 0-10 scale, where 0 represents no burning/squeezing/electric shocks (etc), and 10 represents worst burning/squeezing/electric shocks (etc).
The scores on individual questions are grouped (averaged) into the three following subscales (each subscale scores ranging from 0 to 10):
Washington University School of Medicine
Other
How "Central" is Central Post-stroke Pain? Investigating the Role of Peripheral Sensory Input in Maintaining Central Pain
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02277912
Brain Diseases, Cardiovascular Diseases
View Trial DetailsNCT07202455
Brain Diseases, Cardiovascular Diseases
Clermont-Ferrand, France
View Trial DetailsNCT06387914
Central Post Stroke Pain, Nervous System Diseases
Oxford, Oxfordshire, United Kingdom
View Trial Details